FIG. 3.

Genetic crosses introducing Mo-MuLV into gag-SN transgenic mice (A) To evaluate the antiviral efficacy of Gag-SN fusion proteins in vivo, heterozygous gag-SN/+ mice of lines E and F were crossed with heterozygous Mov13/+ males or homozygous Mov14/Mov14 females. (B) Mov13/+ mice resulting from crosses of gag-SN/+ females with Mov13/+ males lacking the antiviral transgene (Mov13/+; +/+) were compared with their Mov13/+; gag-SN/+ littermates. Only half of the progeny are informative, because the other half do not inherit Mov13. (C) All progeny of the Mov14 crosses are informative. Comparisons are made between Mov14/+; +/+ and Mov14/+; gag-SN/+ siblings.